Pharmaceuticals

While on May 7th, 2025, the Company announced entering into an agreement with Shionogi & Co., Ltd. to transfer the pharmaceutical business and our stake in TORII PHARMACEUTICAL CO., LTD.(''Torii''), a consolidated subsidiary of JT, the JT Group's performance and initiatives described on this page include those associated with the pharmaceutical business and Torii.
Please see the press releases on our website for the details.

As announced on September 1, 2025, the transfer of Torii shares has been completed. Please see the press release on our website for the details.

Striving to create innovative drugs for patients around the world

JT commenced its pharmaceutical business in 1987.
Our mission is to create original and innovative drugs for patients suffering from diseases around the world.

Strengthening our R&D capabilities, a cornerstone of our pharmaceutical business

Yokohama Research Center (Yokohama City, Kanagawa)

Strengthening our R&D capabilities, a cornerstone of our pharmaceutical business

Since 1987, we have been expanding steadily. We opened our Central Pharmaceutical Research Institute in Osaka in 1993, and established a clinical development base outside Japan in 2000 with the addition of our development function to Akros Pharma Inc., our US subsidiary. We focus mainly on the fields of Cardiovascular, Kidney and Skeletal Muscle; Immunology; and Neuroscience.

We are accelerating development in order to provide patients with our drugs as soon as possible. We are enhancing our research and development pipeline, exploring opportunities for strategic in- or out-licensing and strengthening collaboration with our license partners.

Find out more about our pharmaceutical business